The firm has appointed Chloe Garth, Partner, to lead Life Sciences Valuation & Advisory and provide valuation advice to investors, developers and lenders operating across the UK. Garth has considerable experience in the Life Sciences sector, and across the wider London & South East market, a region that includes the Golden Triangle, one of the world’s leading life sciences and biotechnology clusters, with its points at Oxford, Cambridge, and London. Garth joined Cushman & Wakefield from JLL last year.
Tom Nuttall, Head of UK Valuation & Advisory at Cushman & Wakefield, said: “We have a strong track record in the sector and valued more than 30 million sq ft of Life Sciences real estate across the UK last year. Chloe has the specialist knowledge and experience for this new position leading our advice to clients, supporting them in making informed decisions and continuing our growth in this expanding sector.”
Chloe Garth, UK Life Sciences Valuation & Advisory lead at Cushman & Wakefield, said: “Life Sciences is a maturing market in the UK and the construction of more purpose-built stock, both in established and emerging clusters, is starting to make a dent in the supply-demand imbalance. I look forward to leading Cushman & Wakefield’s valuation activity in this fascinating sector.”
Cushman & Wakefield has also appointed Rory MacGregor to lead its Capital Markets activity in the Life Sciences sector. MacGregor was previously a Partner within the firm’s UK Life Sciences advisory team and has been advising clients in the sector since 2019. In his new role, MacGregor will work across EMEA, with a strong focus on the UK, specifically the Golden Triangle, in which Cushman & Wakefield has advised on several notable investment transactions.
These include working on behalf of the London Borough of Sutton to secure Aviva and Socius as funding and development partners for a 1m-sq-ft commercial life sciences campus at the London Cancer Hub, as well as advising GSK on their R&D campus at Stevenage, where Cushman & Wakefield brought in UBS Asset Management and Reef Group to realise the vision for a new biotech ecosystem on the remaining 33 acres of land.
Rory MacGregor, UK Life Sciences Capital Markets lead, Cushman & Wakefield, added: “I’m incredibly excited to lead and build upon Cushman & Wakefield’s strong Life Sciences Capital Markets offering. As a team, we have already been at the forefront of the sector having worked on market leading transactions such as the land disposal at The London Cancer Hub in 2023, GSK’s R&D Headquarters in 2022, and The Oxford Science Park in 2021.”
